Product
Amphotericin B Liposomal
1 clinical trial
1 indication
Indication
Invasive Pulmonary AspergillosisClinical trial
Phase I, Prospective, Randomised, Controlled Study on the Safety and Efficacy of Nebulised Liposomal Amphotericin as an Adjuvant Treatment for Invasive Pulmonary AspergillosisStatus: Completed, Estimated PCD: 2022-11-10